{"id":44016,"date":"2025-10-21T21:13:42","date_gmt":"2025-10-21T13:13:42","guid":{"rendered":"https:\/\/flcube.com\/?p=44016"},"modified":"2025-10-21T21:13:42","modified_gmt":"2025-10-21T13:13:42","slug":"boston-scientific-announces-nalu-medical-acquisition-to-expand-chronic%e2%80%91pain-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44016","title":{"rendered":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio"},"content":{"rendered":"\n<p><strong>Boston Scientific Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/BSX:NYSE\">NYSE: BSX<\/a>)<\/strong> today announced that it has entered into a definitive agreement to acquire the remaining equity of <strong>Nalu Medical, Inc.<\/strong>, a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately <strong>USD\u202f533\u202fmillion<\/strong>, in addition to the equity already held by Boston\u202fScientific since 2017.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\"><strong>Strategic Rationale<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deepening Pain\u2011Management Offerings<\/strong> \u2013 Nalu\u2019s FDA\u2011approved <strong>Nalu Neurostimulation System<\/strong> delivers targeted peripheral nerve stimulation (PNS) for adults with intractable, severe chronic peripheral neuropathic pain (e.g., shoulder, lower back, and knee pain).<\/li>\n\n\n\n<li><strong>Technology Synergy<\/strong> \u2013 The system\u2019s tiny, battery\u2011free implantable pulse generator is wirelessly powered by a small external therapy disc and controlled via a smartphone app, aligning with Boston\u202fScientific\u2019s focus on connected, minimally invasive devices.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 Chronic pain affects over 50\u202fmillion adults in the U.S. alone; the acquisition positions Boston\u202fScientific to capture a growing segment of the rapidly expanding neuromodulation market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-transaction-details\"><strong>Key Transaction Details<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquisition Price<\/strong><\/td><td>USD\u202f533\u202fmillion (upfront) + existing equity stake<\/td><\/tr><tr><td><strong>Previous Investment<\/strong><\/td><td>Boston\u202fScientific has been a strategic investor in Nalu since 2017<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Nalu Neurostimulation System received FDA approval in 2019<\/td><\/tr><tr><td><strong>Technology Overview<\/strong><\/td><td>\u2022 Peripheral nerve stimulation via mild electrical pulses<br>\u2022 Wireless, battery\u2011free implantable pulse generator<br>\u2022 External therapy disc + smartphone\u2011controlled app<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nalu-neurostimulation-system-highlights\"><strong>Nalu Neurostimulation System Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Pain Modulation<\/strong> \u2013 Delivers precise electrical pulses to peripheral nerves, blocking pain signals before they reach the brain.<\/li>\n\n\n\n<li><strong>Minimally Invasive<\/strong> \u2013 Small implant size and battery\u2011free design reduce surgical complexity and improve patient compliance.<\/li>\n\n\n\n<li><strong>Remote Management<\/strong> \u2013 Smartphone app enables clinicians to adjust therapy settings and monitor patient progress in real time.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44019,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[315,4406,1160],"class_list":["post-44016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-boston-scientific","tag-nalu-medical","tag-nyse-bsx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio\" \/>\n<meta property=\"og:description\" content=\"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44016\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T13:13:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio\",\"datePublished\":\"2025-10-21T13:13:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2107.webp\",\"keywords\":[\"Boston Scientific\",\"Nalu Medical\",\"NYSE: BSX\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44016#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44016\",\"name\":\"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2107.webp\",\"datePublished\":\"2025-10-21T13:13:42+00:00\",\"description\":\"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44016\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2107.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2107.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44016#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44016","og_locale":"en_US","og_type":"article","og_title":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio","og_description":"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.","og_url":"https:\/\/flcube.com\/?p=44016","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-21T13:13:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44016#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44016"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio","datePublished":"2025-10-21T13:13:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44016"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44016#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","keywords":["Boston Scientific","Nalu Medical","NYSE: BSX"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44016#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44016","url":"https:\/\/flcube.com\/?p=44016","name":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44016#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44016#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","datePublished":"2025-10-21T13:13:42+00:00","description":"Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire the remaining equity of Nalu Medical, Inc., a privately held medical\u2011device company that develops minimally invasive solutions for patients with chronic pain. The transaction will involve an upfront payment of approximately USD\u202f533\u202fmillion, in addition to the equity already held by Boston\u202fScientific since 2017.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44016#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44016"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44016#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","width":1080,"height":608,"caption":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44016#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston\u202fScientific Announces Nalu\u202fMedical Acquisition to Expand Chronic\u2011Pain Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2107.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44016"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44016\/revisions"}],"predecessor-version":[{"id":44020,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44016\/revisions\/44020"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44019"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}